The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
July 10, 2023
View Complete Issue         Table of Contents 2019 
Two Drugs for RET-Altered Cancers (Retevmo and Gavreto) (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two Drugs for RET-Altered Cancers (Retevmo and Gavreto) (online only)
July 10, 2023 (Issue: 1680)
The oral kinase inhibitors selpercatinib (Retevmo – Lilly) and pralsetinib (Gavreto – Blueprint Medicines/Genentech) have been approved by the FDA for treatment of advanced or metastatic RET-mutant or RET fusion-positive cancers. They are the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two Drugs for RET-Altered Cancers (Retevmo and Gavreto) (online only)
Article code: 1680e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.